- Home
- ABTS vs BCAB Comparison
ABTS vs BCAB Comparison
Compare ABTS & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABTS | BCAB |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 6.4M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ABTS | BCAB |
|---|---|---|
| Price | $0.95 | $3.98 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 506.5K | 29.6K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $0.12 |
| 52 Week High | $10.86 | $6.52 |
Technical Indicators
Market Signals| Indicator | ABTS | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 45.21 | 50.83 |
| Support Level | $0.98 | $3.92 |
| Resistance Level | $1.52 | $6.33 |
| Average True Range (ATR) | 0.10 | 0.44 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 67.26 | 47.49 |
Price Performance
Historical ComparisonAbout ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.